Topical Ruboxistaurin Composition for Hyperpigmentation Without Irritation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperpigmentation, such as hydroquinone, are toxic and ineffective at safe concentrations, and there is a lack of a topical composition for PK inhibitors like ruboxistaurin that is easily administered and non-irritating to the skin.
Innovation Solution
A composition comprising ruboxistaurin or its salts, combined with organic solvents, penetration enhancers, antioxidants, and gelling agents, formulated at 0.1% or 0.8%, is developed for topical application to treat skin disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroquinone is used to treat hyperpigmentation, then melanin synthesis is inhibited, but toxicity to melanocytes occurs and permanent pigment loss or ochronosis may result
Solution Approach 1:
The patent changes the molecular target parameter from non-specific melanin synthesis inhibition (hydroquinone) to selective PKC-β inhibition (ruboxistaurin). This parameter change allows effective melanin synthesis inhibition while avoiding toxicity to melanocytes, as PKC-β is selectively inhibited rather than broad-spectrum melanin pathway components being attacked.
Solution Approach 2:
The patent introduces PKC-β as an intermediary target between UV radiation and melanin synthesis. By inhibiting PKC-β, the pathway between UV exposure and excessive melanin production is blocked, achieving hyperpigmentation treatment without direct toxicity to melanocytes. The intermediary target allows selective intervention in the signaling pathway rather than direct attack on melanin synthesis machinery.
2Reliability
If PK inhibitors like ruboxistaurin are formulated topically, then hyperpigmentation can be treated selectively, but solubility and skin penetration are problematic
Solution Approach 1:
The patent uses penetration enhancers as intermediary substances that facilitate the delivery of ruboxistaurin through the skin barrier. These enhancers create temporary channels or modify the skin structure to allow the PK inhibitor to reach its target in melanocytes, solving the solubility and penetration problems while maintaining selective PKC-β inhibition.
Solution Approach 2:
The patent creates a composite topical formulation combining ruboxistaurin with penetration enhancers and other adjuvant ingredients. This composite material approach addresses the solubility and penetration issues by synergistic combination of components, making the PK inhibitor deliverable through skin while maintaining its selective inhibitory activity.
3Stability of the object's composition
If common solvents are used to formulate PK inhibitors, then the compound can be dissolved, but dermal irritation increases
Solution Approach 1:
The patent changes the solvent system parameters by replacing harsh common solvents with more skin-compatible alternatives. This parameter change in the formulation allows the PK inhibitor to remain soluble while reducing dermal irritation, balancing composition stability with skin tolerance.
Solution Approach 2:
The patent converts the potential harm of needing strong solvents into a benefit by using penetration enhancers that serve dual purposes: they aid in dissolving the PK inhibitor and simultaneously enhance its skin penetration. This converts the problematic need for harsh solvents into an opportunity to improve both solubility and therapeutic delivery while reducing irritation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively inhibits melanin production, reducing hyperpigmentation and minimizing skin irritation, with administration once or twice daily for 4 to 12 weeks.
Implementation Method 1
PKC-β inhibitors referred herein as ruboxistaurin or ruboxistaurin mesylate... inhibit UV induced neo-melanogenesis
Implementation Method 2
an organic solvent and/or a penetration enhancer
Implementation Method 3
an antioxidant
Data Source
AI summary
Provided herein are compositions comprising ruboxistaurin free base and its salts thereof and methods of use for treating conditions of the skin.